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Objective: To evaluate the anti-mycobacterial activity of Melia azedarach L.
(M. azedarach) and Lobelia chinensis Lour. (L. chinensis) extracts against the growth of
Mycobacterium tuberculosis (M. tuberculosis).
Methods: The anti-M. tuberculosis activity of M. azedarach and L. chinensis extracts
were evaluated using different indicator methods such as resazurin microtiter assay
(REMA) and mycobacteria growth indicator tube (MGIT) 960 system assay. The
M. tuberculosis was incubated with various concentrations (50–800 mg/mL) of the ex-
tracts for 5 days in the REMA, and for 4 weeks in MGIT 960 system assay.
Results: M. azedarach and L. chinensis extracts showed their anti-M. tuberculosis ac-
tivity by strongly inhibiting the growth of M. tuberculosis in a concentration-dependent
manner in the REMA and the MGIT 960 system assay. Particularly, the methanol extract
of M. azedarach and n-hexane extract of L. chinensis consistently exhibited their effects
by effectively inhibiting the growth of M. tuberculosis in MGIT 960 system for 4 weeks
with a single-treatment, indicating higher anti-M. tuberculosis activity than other extracts,
and their minimum inhibitory concentrations were measured as 400 mg/mL and 800 mg/
mL, respectively.
Conclusions: These results demonstrate that M. azedarach and L. chinensis extracts not
only have unique anti-M. tuberculosis activity, but also induce the selective anti-
M. tuberculosis effects by consistently inhibiting or blocking the growth of
M. tuberculosis through a new pharmacological action. Therefore, this study suggests the
potential of them as effective candidate agents of next-generation for developing a new
anti-tuberculosis drug, as well as the advantage for utilizing traditional medicinal plants
as one of effective strategies against tuberculosis.1. Introduction
Recently chronic infectious diseases including tuberculosis,
hepatitis, ﬁlariasis, leishmaniasis, amoebiasis caused byEntamoeba histolytica, as well as acute infectious zoonosis such
as malaria, Middle East respiratory syndrome, inﬂuenza and
Ebola, have been occurred or persisted in various countries,
particularly, in less-developed countries globally. Furthermore,
the prevalence of tuberculosis has still been causing a serious
global challenge of drug-resistant tuberculosis such as extensively
drug-resistant tuberculosis (XDR-TB) and multi-drug resistant
tuberculosis (MDR-TB) despite various efforts and studies
worldwide.Mycobacterium tuberculosis (M. tuberculosis) is one
of the major infectious factors causing the highest mortality
through the co-infection with HIV/AIDS as well as the most
dangerous infectious bacteria causing resistant strain through fastrticle under the CC BY-NC-ND license (http://
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Recently, it was estimated that 9.0 million people in the world
were conﬁrmed as new tuberculosis cases in 2013, and 1.1million
of them had HIV-positive response. Particularly, tuberculosis
cases co-infected with HIV/AIDS showed high-infection rates in
the African region compared with other countries, and most of
tuberculosis cases in 2013 and 2014 occurred in Asia (56%) and
the African region (29%) [1,2]. In these aspects, various studies for
the inhibition and/or the treatment of tuberculosis have been
carried out in anti-tuberculosis drug discovery/development
ﬁeld. However, the current anti-tuberculosis drugs not only
showed the limit that can't inhibit the increase of the tuberculosis
patients, but also caused various side effects. Recently, the global
pharmaceutical companies for the development of novel/effective
anti-tuberculosis drugs are testing the repurposed compounds
such as PA-824, SQ109 and linezolid through chemical remod-
eling of the existing drugs, as well as newly developed com-
pounds such as Q203, TMC207, pyridomycin, and thiophenes in
clinical trials [1,3–7]. Nevertheless, the rapid emergence of
tuberculosis including MDR-TB and XDR-TB is still inducing
serious concerns and problems in the public health ﬁeld world-
wide. Recently, various extracts and/or natural products derived
from medicinal plants or traditional oriental medicine were
studied or reported for discovering novel anti-M. tuberculosis
candidate drugs, which are being progressed for developing anti-
tuberculosis drugs of more effective/safe next-generation [8–13].
Furthermore, various medicinal plants of oriental medicine have
been utilized as traditional resources for treating diseases and/or
symptoms such as diabetes, arteriosclerosis, hepatitis, parasite,
cancer both “in vivo” and “in vitro” [14–18].
For these reasons, various studies for developing the effec-
tive/safe anti-tuberculosis drugs with novel mechanisms of ac-
tion, low cytotoxicity, and the least side-effects are urgently
needed to block the tuberculosis. In this aspect, this study was
carried out to evaluate anti-M. tuberculosis effect of Melia
azedarach L. (M. azedarach) and Lobelia chinensis Lour.
(L. chinensis) that are effectively utilized as a medicinal plant in
traditional oriental medicine, and to identify the potential of
them as candidates for developing novel antitubercular drugs.
2. Materials and methods
2.1. Materials
Various drugs used in this study including rifampicin,
isoniazid, resazurin powder and dimethylsulfoxide, were pur-
chased from Sigma-Aldrich Chemical Co. Ltd. (St. Louis, MO,
USA), and MGIT™ 960 system indicator 7 mL growth tubes
with BACTEC™ MGIT™ 960 supplement kit were purchased
from Becton-Dickinson and Company (Sparks, MD, USA). All
other chemicals and reagents were purchased from Merck
Chemical Co., Ltd. (Darmstadt, Germany) and Sigma-Aldrich
Chemical Co., Ltd. (St. Louis, MO, USA).
2.2. Preparation and extracts of medicinal plants
The dried roots and barks of M. azedarach and dried roots,
stem, leaves and ﬂowers of L. chinensis were provided by the
Oriental Medical Center, Kyung Hee University (Seoul, Re-
public of Korea) and Bundang Oriental Hospital, Dongguk
University (Seoul, Republic of Korea) for this study. TheM. azedarach and L. chinensis were extracted according to
solvent extraction system as follows: Five hundred grams of
each powdered M. azedarach and L. chinensis were indepen-
dently extracted with 4 L of n-hexane, chloroform, ethyl acetate,
methanol, and distilled water at room temperature for 24 h,
respectively. These extracts were ﬁltered using ﬁlter paper and a
vacuum pump, and then were evaporated under reduced pressure
using a rotary evaporator in a vacuum at 45 C. The extracts
were lyophilized after evaporation. All extracts were ﬁltered
using a 0.45 mm syringe ﬁlter (Roshi Kaisha, Ltd., Tokyo,
Japan) and stored at −80 C until use.
2.3. Preparation of anti-M. tuberculosis drugs
The anti-M. tuberculosis ﬁrst-line drugs, isoniazid, was dis-
solved in sterile distilled water, and rifampicin was dissolved in
dimethylsulfoxide, to a concentration of 50mg/mL according to the
manufacturer's instruction. The anti-M. tuberculosis ﬁrst-line drugs
were used as reference standard drugs. All compoundswere ﬁltered
using 0.45 mmmembrane syringe ﬁlter (RoshiKaisha, Ltd., Tokyo,
Japan) before use and stored at −80 C deep-freezer until use.
2.4. Preparation andgrowth conditions ofM. tuberculosis
M. tuberculosis H37Rv (ATCC 27294) and H37Ra (ATCC
25177) used in this study were purchased from American Type
CultureCollection (Manassas,VA,USA).M. tuberculosisH37Rv
and H37Ra were grown in Middlebrook 7H9 broth (Difco Lab-
oratories, Detroit, MI, USA) supplemented with 10% (v/v) oleic
acid/albumin/dextrose/catalase enrichment (Becton–Dickinson
and Company, Sparks, MD, USA) and 0.05% (v/v) Tween 80
(Sigma–Aldrich Chemical, St. Louis, MO, USA) to the log phase
at 37 C for 4–5 weeks on shaking incubation of 120 r/min.
2.5. Drug susceptibility testing of M. tuberculosis
The in vitro anti-M. tuberculosis activity of M. azedarach
and L. chinensis extracts was conﬁrmed by resazurin microtiter
assay (REMA) using a 96-well micro-plate. Brieﬂy,
M. tuberculosis was grown in fresh Middlebrook 7H9 broth
supplemented with 10% (v/v) oleic acid/albumin/dextrose/
catalase enrichment and 0.05% (v/v) Tween 80 until the culture
reached a turbidity equal to that of 1.0 McFarland standard
(3.0 × 108 CFU/mL) at 37 C. The bacteria were adjusted to a
density of 2 × 106 CFU/mL in fresh culture broth. Finally, the
bacterial suspensions were inoculated into all wells of a 96-well
microtiter plate containing ﬁnal concentrations (50–200 mg/mL)
of M. azedarach and L. chinensis extracts and anti-tuberculosis
ﬁrst-line drugs (1.25–5.00 mg/mL). M. tuberculosis growth
controls containing no anti-M. tuberculosis ﬁrst-line drugs and
blank controls without inoculation were also included. The 96-
well plates, covered with lids, placed in a plastic bag, were
incubated at 37 C for 5 days. After incubation, 20 mL of freshly
prepared 0.05% (w/v) resazurin solution was added to all wells,
and the plates were re-incubated at 37 C for 36 h. A change in
color from blue to pink indicating bacterial growth was
observed after 36 h of incubation. The minimum inhibitory
concentration (MIC) was expressed as the lowest concentration
of the drug that inhibited M. tuberculosis growth or prevented
change in color of the resazurin solution from blue to pink based
on a REMA.
Table 1
The inhibitory effects of M. azedarach and L. chinensis extracts against
the growth of M. tuberculosis (H37Rv and H37Ra) determined by the
REMA.
Medicinal plant Extracts Concentrations (mg/mL)
H37Rv H37Ra
200 100 50 200 100 50
M. azedarach n-Hexane extract + + − + + −
Chloroform extract + + +/− + + +/−
Ethyl acetate + + +/− + + +/−
Methanol extract + + +/− + + +/−
H2O extract + + +/− + + +/−
L. chinensis n-Hexane extract + + +/− + + +/−
Chloroform extract + + − + + −
Ethyl acetate + + +/− + + +/−
Methanol extract + + +/− + + +/−
H2O extract + + +/− + + +/−
The M. tuberculosis was incubated with different concentrations (50–
200 mg/mL) of the extracts at 37 C for 5 days. The “+” and “−” sign
indicates anti-M. tuberculosis activity and no activity respectively, and
“+/−” sign shows 55%–65% inhibitory rates of the extracts against the
growth of M. tuberculosis.
Table 2
MICs of M. azedarach and L. chinensis extracts against the growth of
M. tuberculosis (H37Rv and H37Ra) determined by different anti-
M. tuberculosis indicator assays.
Medicinal plants Extracts MIC (mg/mL)
REMA MGIT 960 system
M. azedarach n-Hexane extract 100 > 800
Chloroform extract 100 > 800
Ethyl acetate 100 > 800
Methanol extract 100 400
H2O extract 100 > 800
L. chinensis n-Hexane extract 100 800
Chloroform extract 100 > 800
Ethyl acetate 100 > 800
Methanol extract 100 > 800
H2O extract 100 > 800
M. tuberculosis (H37Rv and H37Ra) were incubated with different
concentrations (25–800 mg/mL) of the extracts at 37 C, and their sus-
ceptibility was evaluated by different anti-M. tuberculosis-indicator as-
says. The results of the REMA and the MGIT 960 system assay were
determined after 5 days and 28 days of incubation, respectively.
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by MGIT 960 system assay
For evaluate anti-M. tuberculosis effects ofM. azedarach and
L. chinensis extracts against the growth of M. tuberculosis, the
drug susceptibility testing of the strain was further performed
using the BACTEC™ MGIT 960 system (Becton, Dickinson
and Company, Sparks, MD, USA). In brief, 100 mL of a sus-
pension of M. tuberculosis culture, adjusted to 9.6 × 106 CFU/
mL, was inoculated in an MGIT growth media tube with
BACTEC™ MGIT 960 growth supplement (Becton, Dickinson
and Company), which were incubated with different concen-
trations (25–800 mg/mL) of the extracts and anti-M. tuberculosis
ﬁrst-line drugs (10 mg/mL), and M. tuberculosis growth controls
containing no anti-M. tuberculosis ﬁrst-line drugs were also
included. They were incubated into the BACTEC™ MGIT 960
system device for 4 weeks for the accurate determination of
M. tuberculosis drug-susceptibility.
2.7. Statistical analysis
All results were expressed as mean ± SD of three indepen-
dent experiments. Statistical analysis of the data was performed
using the Student's t-test and One-way ANOVA. P < 0.05 was
considered to be statistically signiﬁcant.
3. Results
3.1. Evaluation of anti-M. tuberculosis activity of the
extracts using REMA
The anti-M. tuberculosis activity of M. azedarach and
L. chinensis extracts were evaluated using the REMA. The
M. azedarach and L. chinensis were independently extracted
using different solvents at room temperature for 24 h, respec-
tively (Figure 1). After the bacteria were incubated with various
concentrations (50–200 mg/mL) of the extracts and anti-
M. tuberculosis ﬁrst-line drugs (rifampicin and isoniazid, 1.25–
5.00 mg/mL) for 5 days, the growth of M. tuberculosis were
markedly inhibited in a concentration-dependent manner, and
then their viabilities were 0% at a concentration of 100 mg/mL of
all extracts (Table 1). The minimal inhibitory concentration
(MIC) values of all extracts against the viability of
M. tuberculosis were measured as 100 mg/mL (Table 2).
Furthermore, the extracts obviously demonstrated their
M. tuberculosis-inhibitory effect through the REMA. Although
the superiority and speciﬁcity between the extracts regarding
anti-M. tuberculosis effect were not conﬁrmed in the REMA, theM. azedarach
Extraction with n-hexane, chloroform, ethyl 
acetate, methanol, and distilled water for 24 
h, respectively
n-Hexane
extract
Ethyl acetate
extract
Chloroform
extract
BA
Methanol
extract
Distilled
water extract
The strong anti-
M. tuberculosis
activity
Figure 1. Extraction process of M. azedarach (A) and L. chinensis (B).extracts showed similar anti-M. tuberculosis activity in both
M. tuberculosis H37Ra and M. tuberculosis H37Rv. These re-
sults indicate that M. azedarach and L. chinensis extracts have
not only anti-M. tuberculosis effects by strongly inhibiting the
growth of M. tuberculosis but also the potential that can beL. chinensis 
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date agents through their new pharmacological activity.
3.2. Anti-M. tuberculosis effects of the extracts using the
MGIT 960 system assay
The anti-M. tuberculosis effects of the extracts were further
evaluated using the MGIT 960 system assay. The bacteria were
incubated with various concentrations (25–800 mg/mL) of the
extracts and anti-M. tuberculosis ﬁrst-line drugs (10 mg/mL) in
an MGIT growth media tube of the BACTEC™ MGIT 960
system device for drug susceptibility testing for 4 weeks, and
their growth units were markedly inhibited in a concentration-
dependent manner (Figure 2). Particularly, the methanol
extract of M. azedarach and n-hexane extract of L. chinensis
strongly inhibited the growth of M. tuberculosis compared with
other extracts. When M. tuberculosis was incubated with
200 mg/mL of the methanol extract of M. azedarach, their
growth units were detected at about 8.7 days, whereas 400 mg/
mL of the methanol extract strongly inhibited the growth of
M. tuberculosis compared with other extracts, and the growth
unit of M. tuberculosis was not detected until 28th day.
Furthermore, when M. tuberculosis was incubated with 400 mg/
mL of the n-hexane extract of L. chinensis, their growth units
were detected at 20.6 days, whereas 800 mg/mL of the n-hexane
extract strongly inhibited the growth of M. tuberculosis, and the
growth unit of M. tuberculosis was not detected until 28th day.
In this MGIT 960 system assay, the methanol extract of
M. azedarach and the n-hexane extract of L. chinensis consis-
tently inhibited the growth of M. tuberculosis for 4 weeks with a
single treatment (400 mg/mL and 800 mg/mL) respectively, and
they showed more effectively the selective anti-M. tuberculosis
activity as well as anti-M. tuberculosis action compared with
other extracts. In addition, the extracts indicated higher activity
against M. tuberculosis H37Ra than M. tuberculosis H37Rv in
the MGIT 960 system assay (Figure 2). Particularly, the differ-
ences in anti-M. tuberculosis activity of them were obviously
conﬁrmed in the MGIT 960 system assay compared with the
REMA assay (Table 2). These results demonstrate that the ex-
tracts not only induce anti-M. tuberculosis activity causing the
inactivation of M. tuberculosis by effectively or consistently
inhibiting the growth of M. tuberculosis, but also have unique
anti-M. tuberculosis properties that inhibit or block the growth
of M. tuberculosis in a concentration-dependent manner.25 μg/mL
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Figure 2. The anti-M. tuberculosis activity of M. azedarach and L. chinensis
Control: Untreated growth-M. tuberculosis; R: Rifampicin 10 mg/mL; I: Isoniazid
D: Methanol extract; E: Distilled water extract. The M. tuberculosis (H37Rv an
the extracts in the MGIT 960 system device at 37 C for 4 weeks, respectivel
control.4. Discussion
The recent zoonotic diseases such as Middle East respiratory
syndrome, avian inﬂuenza andEbola have been occurred in various
countries worldwide through diverse infectious pathways, partic-
ularly, in Asia, Middle East and Africa. Furthermore, the serious
infectious pathogens such as inﬂuenza, M. tuberculosis, and
methicillin-resistant Staphylococcus aureus have strongly
enhanced their infectivity and viability through resistance or
adaptability to drugs as well as environmental variation for the past
decades, which induces serious difﬁculty to treatment and pre-
vention of the disease as well as the development of the effective
drug. In particular, these diseases have caused high risk symptoms
to young children whose immune function is low and the elderly
who have other underlying diseases or complications compared
with normal adults. In this aspect, tuberculosis is a disease to cause
infection through droplets, which has been causing high mortality
and prevalence rate compared with other contagious diseases
worldwide. Tuberculosis was one of the leading causes of death
among various infectious diseases in 2013 and 2014 globally,
particularly, in Africa [1,2]. It is the most dangerous infectious
disease causing complications such as bronchiectasis, emphy-
sema, and pneumothorax through chronic symptom. In addition,
the rapid increase and appearance of XDR-TB/MDR-TB imply
an urgent need to develop anti-tuberculosis drugs of effective/safe
next-generation for treating tuberculosis. Until recently, despite
various efforts to discover and to develop new anti-tuberculosis
drugs, the development of effective/safe anti-tuberculosis drugs is
still facing with direct or indirect-difﬁculty including the cost or
time as well as the economic aspect and the proﬁtability of phar-
maceuticals. Furthermore, the overuse of antibiotics and antibac-
terial drugs has rapidly increased the prevalence and incidence rate
of resistant-tuberculosis such asXDR-TBandMDR-TB,which has
caused more difﬁculty to treat tuberculosis-patients compared with
the past. In addition, the current anti-tuberculosis drugs induce
various/serious side effects including hepatotoxicity, ototoxicity,
and nephrotoxicity. In this aspect, as one of feasible alternatives for
overcoming limitations of the drug's side effects, particularly,
including rifampicin, isoniazid, ethambutol and moxiﬂoxacin,
various studies for developing anti-tuberculosis drugs were re-
ported from active substances derived from traditional diverse
medicinal plants and biological resources [19–23]. However, anti-
tuberculosis agents of effective/safe next-generation that can be
utilized or used as potential/novel ﬁrst-line anti-tuberculosis drugs,N
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compounds, have not yet been reported in the global pharmaceu-
tical market.
In this perspective, the new pharmacological activity of
medicinal plants used in oriental medicine or traditional medi-
cine can provide the advantages of both the safety and efﬁcacy
compared with newly developed drugs such as semi-synthetic
compounds or biomedicine, which may be used or utilized as
one of effective/feasible strategies for developing anti-
tuberculosis drugs of effective/safe next-generation. Moreover,
the plants selected from the existing medicinal plants through
new pharmacological action may increase the potential which
can be utilized as a useful/feasible resource for developing new
substances in a medical ﬁeld. For these reasons, this study has
been focused on major key points for the discovery of new
candidate substances as one of different strategies for developing
anti-tuberculosis drugs, which has included crucial factors such
as the minimization of side effects and the safety of drugs, as
well as the ﬁnding of novel pharmacological activity and func-
tion of the medicinal plants used in Korean traditional medicine.
In these aspects, M. azedarach and L. chinensis are medicinal
plants that are used as biological resources of traditional oriental
medicine in Korea, Japan and China as well as various countries
and regions globally, which include various bioactive sub-
stances. Until recently, pharmacological activity and function of
them have been variously reported as follows: (1) the aqueous
extracts from M. azedarach induce the effect of wound healing
by activating the growth of keratinocyte [24]; (2) the
pediculicidal activity of ethanol extracts of M. azedarach [25];
(3) the leaves and bark extracts of M. azedarach through
cyclooxygenase-2 and the inducible NO synthase inhibition
cause anticancer activity and anti-inﬂammatory effects [26–28];
(4) the anti-diabetic activity of ethanol extract of M. azedarach
[29]; (5) the anti-parasitic effect of hexane extract of
M. azedarach against gastrointestinal nematodes [30]; (6) the
antibacterial effect and antifungal activity of the extracts of
M. azedarach against pathogenic bacterial and fungus strains
[31,32]; (7) the methanol extracts and the compounds isolated
from L. chinensis induce anti-oxidant activity and anti-
inﬂammatory effects through the nuclear factor-kB pathways
[33,34]; (8) the anti-viral effects of L. chinensis extracts in mouse
model infected by herpes simplex virus type 1 [35]; (9) the
anticancer effects of the compounds isolated from L. chinensis
against human lung cancer cells [36,37].
Taken together, these studies show substantial evidence that
M. azedarach and L. chinensis can be used or utilized as ther-
apeutic agents through their unique pharmacological activity and
function in both “in vitro” and “in vivo”. However, despite the
pharmacological activity or actions of them identiﬁed through
these studies, their anti-tubercular activity have not yet been
reported in both “in vitro” and “in vivo”. For this reason, this
study has been begun from hypothesis that M. azedarach and
L. chinensis may strongly inhibit or block and effectively
modulate the growth of M. tuberculosis. As mentioned above,
the results of this study showed novel anti-tubercular activity
of M. azedarach and L. chinensis extracts by effectively
inhibiting the growth of M. tuberculosis through their novel
pharmacological activity and properties. Particularly, anti-
M. tuberculosis activity and the ability of M. azedarach and
L. chinensis extracts were obviously demonstrated through
different M. tuberculosis susceptibility-indicator assays such as
the REMA and MGIT 960 system assay, and they consistentlyshowed their anti-M. tuberculosis activity by strongly inhibiting
the growth of M. tuberculosis for 4 weeks with a single treat-
ment (400 mg/mL and 800 mg/mL) in MGIT 960 system assay,
respectively. In addition, the speciﬁcity and differences in anti-
M. tuberculosis activity of them were obviously conﬁrmed in the
MGIT 960 system assay compared with the REMA assay, and
the methanol extract of M. azedarach more effectively inhibited
the growth of M. tuberculosis compared with those of
L. chinensis extracts. These results imply that the intracellular
signaling-pathways for replication as well as key-proteins for
regulating cell cycle in cytoplasm that accelerate the growth of
M. tuberculosis and/or functions of the cell wall of
M. tuberculosis are strongly inhibited or deactivated by the
binding of the extracts. Furthermore, the extracts showed higher
anti-M. tuberculosis activity in M. tuberculosis H37Ra than
M. tuberculosis H37Rv in the MGIT 960 system assay, and it
suggests that these results can be associated with differences in
pathogenesis and virulence of the two strains or different path-
ogenic phenotypes between H37Rv and H37Ra.
In conclusion, M. azedarach and L. chinensis extracts effec-
tively inhibited the growth ofM. tuberculosis that can cause active
tuberculosis in those with weakened immune systems through
their novel pharmacological activity or function, and their anti-
M. tuberculosis activity were obviously demonstrated through
different anti-M. tuberculosis indicator assays such as the MGIT
960 system and the REMA. These results showed that the
effective use of M. azedarach and L. chinensis extracts can be
utilized as potential anti-M. tuberculosis agents for consistently
inhibiting or blocking tuberculosis causing various complications
in clinical ﬁelds. Therefore, this study provides signiﬁcant evi-
dence and the potential that M. azedarach and L. chinensis ex-
tracts can be used or utilized as promising candidate substances
for developing novel anti-tubercular drugs of the effective next-
generation in the near future through their new pharmacological
activity concerning anti-M. tuberculosis effect.
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